University College, London

This phase 3 trial compares two chemotherapy regimens (ABVD vs A2VD) for people with newly diagnosed, early-stage Hodgkin lymphoma. About 1042 participants will receive 3-4 cycles of chemo, with a mid-treatment PET scan to guide further therapy. The goal is to see which regimen b…

This early-phase study tests whether giving the immunotherapy drug ipilimumab before standard surgery and chemoradiation is safe and helpful for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 16 adults will receive up to two doses of ipilimumab befor…

This study tests whether a digital home monitoring system called CirrhoCare can reduce unplanned hospital visits for people with decompensated cirrhosis. About 214 adults with cirrhosis will be randomly assigned to use the CirrhoCare system at home or receive standard care. The m…

This early-phase trial tests a new type of CAR T cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. The therapy uses immune cells engineered to recognize and attack myeloma cells through two targets (BCMA and CD19). The mai…

This study tests whether proton beam radiation can slow or stop the growth of a rare chest cancer called malignant pleural mesothelioma. About 148 adults with early-stage disease will receive radiation to one side of the chest. The goal is to see if this treatment helps people li…

This study tests a smartphone app called neoSCB that screens newborn babies for jaundice by taking a photo of the white part of the eye. Jaundice affects about 60% of newborns and, if missed, can cause serious brain damage. The app aims to provide a low-cost, accurate way to deci…

This study compares two types of robotic-assisted total knee replacement surgery for people with knee osteoarthritis. One method uses cement to fix the new joint in place, while the other does not. The goal is to see which approach helps patients feel more like their knee is natu…

This study is collecting spinal fluid and blood samples from 2,500 people at different stages of Huntington's disease. The goal is to find biological markers that can help researchers develop new treatments. Participants include people with Huntington's, their family members, and…